Know Cancer

forgot password

Treatment With the Combination of Epirubicin and Paclitaxel Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer. A Multicenter, Randomized Phase III Study

Phase 3
18 Years
Open (Enrolling)
Metastatic Breast Cancer

Thank you

Trial Information

Treatment With the Combination of Epirubicin and Paclitaxel Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer. A Multicenter, Randomized Phase III Study

Inclusion Criteria:

- Morphologically proven breast carcinoma

- Written patient consent must be obtained

- Measurable disease (i.e. at least one lesion that can be accurately measured in at
least one dimension as ≥20 mm by conventional techniques, or as ≥10 mm by spiral CT
scan) as defined in section 8.

- Lytic and blastic bone metastases as only site of recurrence are allowed

- Age 18 years or older

- ECOG performance status 0-2

- Life expectancy of at least three months

- Adequate cardiac functions

- Adequate hematological, renal and hepatic functions

- Patient must be accessible for treatment and follow-up.

Exclusion Criteria:

- Treatment-free interval less than one year, if previous adjuvant, neoadjuvant or
after radically treated locoregional recurrence given regimen contained
anthracycline, taxane or capecitabine. This limitation does not apply for regimens
containing other than the drugs mentioned

- During adjuvant treatment obtained cumulative doses exceeding 375 mg/m2 for
doxorubicin, or 550 mg/m2 for epirubicin, abnormal ECG or reduced cardiac function
measured by left ventricular ejection fraction (LVEF).

- Indication for the use of trastuzumab (Herceptin) as first-line treatment in patients
with tumor overexpressing c-erbB2.

- Any previous chemotherapy for metastatic disease, except for radically treated
locoregional relapse

- Neoplasm other than breast carcinoma, except for non-melanoma skin cancer or
curatively treated carcinoma in situ of the cervix, diagnosed during the past five

- Pregnancy or lactation

- Known brain metastases

- History of atrial or ventricular arrhythmias and/or congestive heart failure, even if
medically controlled. History of clinical and electrocardiographically documented
myocardial infarction

- Preexisting motor or sensory neuropathy ≥ grade 2 according to NCI CTC 2.0 criteria
(severe paresthesia and/or mild weakness, or worse)

- Severe hepatic or renal impairment (for capecitabine: calculated creatinine clearance
below 30 ml/min; for calculation, see p. 5.1.4) not allowing for adequate use of the
proposed regimens

- History of known dihydropyrimidine dehydrogenase (DPD) deficiency (severe reaction on
previous treatment with fluorouracil, e.g experience of mucositis, hand-foot
syndrome, or diarrhea)

- Active infection or other serious underlying medical condition which would impair the
ability of the patient to receive protocol treatment, including prior allergic
reactions to drugs containing cremophor, such as teniposide, cyclosporin or vitamin K

- Dementia or significantly altered mental status that would prohibit the understanding
and giving of informed consent.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Time to progression

Outcome Description:

Time to progression comparing treatment with ET vs. TEX in patients with advanced breast cancer.

Outcome Time Frame:

Every 9 weeks during treatment and every three months after termination of treatment

Safety Issue:


Principal Investigator

Thomas Hatschek, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Karolinska University Hospital


Sweden: Medical Products Agency

Study ID:

TEX trial



Start Date:

December 2002

Completion Date:

March 2012

Related Keywords:

  • Metastatic Breast Cancer
  • Breast Neoplasms